Welcome to the international HTA database

Showing [25318 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2026	National Institute for Health and Care Excellence (NICE)	Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida (terminated appraisal). NICE technology appraisal guidance 1154
2026	Scottish Health Technologies Group (SHTG)	Computed tomography fractional flow rate (CT-FFR)
2026	National Institute for Health and Care Excellence (NICE)	Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1150
2026	Scottish Health Technologies Group (SHTG)	Specialist interventions for managing chronic non-malignant pain in adults
2026	National Institute for Health and Care Excellence (NICE)	Inebilizumab for treating immunoglobulin G4-related disease (terminated appraisal). NICE technology appraisal guidance 1151
2026	Scottish Health Technologies Group (SHTG)	Surgical care practitioners
2026	National Institute for Health and Care Excellence (NICE)	Digital technologies to support self-management of asthma: early-use assessment. NICE HealthTech guidance 778
2026	NIHR Health Services and Delivery Research programme	Referral pathways into the NHS Digital Weight Management Programme for musculoskeletal and perioperative patients: rapid process evaluation
2026	National Institute for Health and Care Excellence (NICE)	Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment. NICE HealthTech guidance 779
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid for prostate cancer]
2026	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evaluation of the regulations governing a tiered system of emergency structures in hospitals]
2026	NIHR Health Technology Assessment programme	Addition of early vocational advice to usual primary care on sickness absence in employed adults: exploratory findings from the discontinued WAVE Randomised Controlled Trial
2026	NIHR Health Technology Assessment programme	Clinical and cost-effectiveness of medical management versus surgery for deep infiltrating endometriosis: synopsis from the DIAMOND RCT
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Immunological assays of tacrolimus and cyclosporine]
2026	Andalusian Health Technology Assessment Area (AETSA)	[Assessment of body composition and muscular functionality in the oncology patient. Systematic review]
2026	National Institute for Health and Care Excellence (NICE)	Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy. NICE technology appraisal guidance 1126
2026	NIHR Health Services and Delivery Research programme	Independence and interdependence of non-medical practitioners in the emergency care skill-mix (SKILLMix-ED): a multi-method study to develop a measurement tool
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Relevance of intraperitoneal chemotherapy for preventing or treating neoplasms of the peritoneal surfaces - peritoneal metastases secondary to colorectal cancer]
2026	National Institute for Health and Care Excellence (NICE)	Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal). NICE technology appraisal guidance 1124
2026	NIHR Health Services and Delivery Research programme	Accounting for needs in geographical health care resource allocation
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Robotic surgery – relevance and optimal framework for three oncological indications: total hysterectomy for endometrial cancer, radical prostatectomy for prostate cancer, and partial nephrectomy for renal cancer]
2026	National Institute for Health and Care Excellence (NICE)	Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal). NICE technology appraisal guidance 1125
2026	NIHR Health Services and Delivery Research programme	Lifeguard Pharmacy - A feasibility trial of a novel pharmacy-based intervention for people experiencing domestic abuse and/or suicidal ideation
2026	NIHR Health Services and Delivery Research programme	Developing the evidence and associated service models to improve pain management in older people living with frailty: a synopsis of the POPPY mixed method, co-design study
2026	National Institute for Health and Care Excellence (NICE)	Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal). NICE technology appraisal guidance 1123
2026	NIHR Health Technology Assessment programme	Development and description of Early Stroke Specialist Vocational Rehabilitation delivered in the RETAKE trial
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[The integration of care and services for the benefit of vulnerable populations]
2026	NIHR Health Technology Assessment programme	Prevention and treatment of incontinence-associated dermatitis through optimising care: the PREVENT-IAD Synopsis
2026	National Institute for Health and Care Excellence (NICE)	Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 1122
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Teprotumumab (TEPEZZA)]
2026	National Institute for Health and Care Excellence (NICE)	Acoramidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 1121
2026	NIHR Health Services and Delivery Research programme	Evidence base to inform health service configuration for abortion provision: the SACHA (Shaping Abortion for Change) multi-component study
2026	Austrian Institute for Health Technology Assessment (AIHTA)	Artificial intelligence for hospital documentation support - a scoping review of current use cases
2026	National Institute for Health and Care Excellence (NICE)	Avelumab with axitinib for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 1120
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Sentinel injuries: suggestive signs of inflicted injuries in precruising infants]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Governance for improving the quality of primary healthcare]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of robotic surgery: total hysterectomy for endometrial cancer, radical prostatectomy for prostate cancer, and partial nephrectomy for renal cancer]
2026	National Institute for Health and Care Excellence (NICE)	Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 1118
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Treatment algorithm for acute lymphoblastic leukemia in adults]
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Sacituzumab Govitecan (TRODELVY)]
2026	National Institute for Health and Care Excellence (NICE)	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 1119
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tumor biomarkers related to the management of advanced thyroid cancer]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Effectiveness and safety of robotic surgery: rectal and colon cancers, benign and malignant pancreatic tumours, and obesity]
2026	National Institute for Health and Care Excellence (NICE)	Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment. NICE HealthTech guidance 766
2026	NIHR Health Technology Assessment programme	Manualised package intervention to achieve treatment adherence in people with tuberculosis: the IMPACT pilot cluster-RCT
2026	NIHR Health Services and Delivery Research programme	Recovery Colleges for post-diagnostic dementia support: the DiSCOVERY realist evaluation synopsis
2026	National Institute for Health and Care Excellence (NICE)	Digital self-help for eating disorders: early value assessment. NICE HealthTech guidance 768
2026	NIHR Health Services and Delivery Research programme	Pressure Ulcer Prevention at Home for People with Long-term Neurological Conditions, Carers and Personal Assistants: synopsis – a participatory, qualitative study (PUP@Home1)
2026	Health Technology Wales (HTW)	Artificial intelligence-assisted ultrasound for the detection of deep vein thrombosis
2026	NIHR Health Technology Assessment programme	Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic model
2026	Health Technology Wales (HTW)	Salvage high dose rate brachytherapy (HDR-BT) for localised relapse of prostate cancer after prior curative intent radiotherapy
2026	NIHR Health Services and Delivery Research programme	Attracting, recruiting, and retaining registered nurses and care workers in care homes: the REACH realist review
2026	Norwegian Medical Products Agency (NOMA)	[Blood-based biomarker tests for Alzheimer's disease: a mapping review]
2026	NIHR Health Services and Delivery Research programme	Improving collaborative inter-agency systems and practice in self-neglect: a realist review and interview study
2026	Austrian Institute for Health Technology Assessment (AIHTA)	AI-supported chest x-ray analysis for lung cancer detection - systematic review of clinical outcomes and organisational implications
2026	Norwegian Medical Products Agency (NOMA)	[Repetitive transcranial magnetic stimulation for treatment-resistant moderate and severe depression: a health technology assessment]
2026	NIHR Health Services and Delivery Research programme	Integrated pharmacist and third sector outreach support for people experiencing homelessness: a synopsis of the PHOENIx community pharmacy-based pilot randomised controlled trial
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Antibiotic prophylaxis for gynecological and obstetrical surgeries and procedures]
2026	NIHR Health Services and Delivery Research programme	Exploring the use of pre-hospital pre-alerts and their impact on patients, ambulance service and emergency department staff: a mixed-methods study
2026	Austrian Institute for Health Technology Assessment (AIHTA)	Structured medication review for polypharmacy – systematic review
2026	NIHR Health Technology Assessment programme	PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data
2026	NIHR Health Technology Assessment programme	A novel methodology using direct patient contact and UK national registries to collect long-term data from randomised trials: TARGIT-X – an extended follow-up study of the TARGIT-A trial of targeted intraoperative radiotherapy for breast cancer
2026	Center for Outcomes Research and Economic Evaluation for Health (C2H)	[Cost-effectiveness evaluation of Brivaracetam (Briviact)]
2026	Center for Drug Evaluation (CDE)	[HTA Rapid report- Theranova 400/500 (capillary dialyzer)]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Pharmacological treatment – anxiety disorder or obsessive-compulsive disorder in young people aged 12 to 17]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Immediate hypersensitivity to parenteral cancer treatments]
2026	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[An evaluation of the safety, efficacy, clinical effectiveness, efficiency and organisational aspects of the implementation of model-based dosing systems for the treatment of inflammatory bowel disease]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Imaging surveillance of a degenerative dilatation of the ascending aorta in adults]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Digital self-care solutions for diabetes]
2026	NIHR Health Technology Assessment programme	A novel approach to the assessment of repeat self-harm in prisoners: development and validation of a tool to bridge assessment and treatment (RAPSS)
2026	NIHR Health Services and Delivery Research programme	Optimising rapid prenatal exome sequencing in the NHS genomic medicine service: the EXPRESS Synopsis
2026	NIHR Health Services and Delivery Research programme	Responding to people in danger: a community pharmacy response service for domestic abuse and suicidal ideation, a development and feasibility study
2026	Center for Drug Evaluation (CDE)	[HTA Rapid report- Steerable sheath]
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[The relevance of hearing screening for workers in the Quebec context]
2026	Center for Drug Evaluation (CDE)	[HTA Rapid report- Suspensory fixation device]
2026	Health Technology Wales (HTW)	Wearable and bed-based technologies to detect tonic-clonic seizures in people with epilepsy
2026	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Suvanto Care Safety Service
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prioritisation of knowledge needs concerning home care for older adults]
2026	Agency for Care Effectiveness (ACE)	Complement inhibitors for treating paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[National plan for better addiction treatment]
2026	Swiss Federal Office of Public Health (FOPH)	Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus
2026	Agency for Care Effectiveness (ACE)	Eplontersen and vutrisiran for hereditary transthyretin amyloidosis with polyneuropathy
2026	NIHR Health Technology Assessment programme	Newborn screening for severe combined immunodeficiency in the NHS newborn blood spot screening programme: a systematic review
2026	Institut national d'excellence en sante et en services sociaux (INESSS)	[Digital self-care solutions for chronic insomnia]
2026	Swiss Federal Office of Public Health (FOPH)	Valerian extracts for sleep disorders, anxiety or restlessness
2026	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Newborn screening of mucopolysaccharidosis type 1]
2026	Agency for Care Effectiveness (ACE)	Amivantamab for previously treated, locally advanced or metastatic EGFR exon 19 deletion or exon 21 L858R substitution mutation-positive non-small-cell lung cancer
2026	Agency for Care Effectiveness (ACE)	Amivantamab for previously untreated, locally advanced or metastatic EGFR exon 20 insertion mutation-positive non-small-cell lung cancer
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostic accuracy of different index tests in diagnosing suspected peanut allergy]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Home based health care: enablers and barriers to quality of care and patient safety]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Methods, ways of working, and efforts to prevent recidivism for perpetrators of domestic or honor-based violence]
2027	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Diagnostics of endometriosis]
2027	Health Information and Quality Authority (HIQA)	Health Technology Assessment (HTA) of the transition to, and coordination of, adult healthcare services for individuals with severe neurological impairment
2027	Gesundheit Osterreich GmbH (GOeG)	[Educational interventions to promote the rational prescribing of antibiotics for children and adolescents]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Guideline synopsis for updating the DMP ‘Obesity – adults’]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relationship between volume of services and quality of treatment outcome in corrective surgery for esophageal atresia]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Selection of interventions for the second opinion procedure according to §27b Social Code Book V]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Equinus foot: which non-drug treatment methods are helpful for those affected?]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence search for the S3 guideline on the diagnosis, therapy and follow-up of extracranial carotid stenosis]
2027	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Evidence search for the S3 guideline on the diagnosis, therapy and follow-up of extracranial carotid stenosis]